X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Araris will use its proprietary linker-conjugation platform to generate next-generation novel ADCs against undisclosed targets provided by Taiho.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Araris Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2023
Details:
Under the agreement, Taiho will obtain option rights for PhOx430, a first-in-class small molecule targeting GnT-V and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in Asia.
Lead Product(s): PhOx430
Therapeutic Area: Oncology Product Name: PhOx430
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Phost\'in Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 25, 2023
Details:
TS-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption by the gastrointestinal tract, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CDHP).
Lead Product(s): Tegafur,Gimeracil
Therapeutic Area: Oncology Product Name: TS-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
Taiho has also completed its acquisition of Cullinan Oncology’s subsidiary, Cullinan Pearl Corp. (Cullinan Pearl) which has worldwide rights outside of Japan* to CLN-081/TAS6417.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Cullinan Therapeutics
Deal Size: $405.0 million Upfront Cash: $275.0 million
Deal Type: Collaboration June 23, 2022
Details:
Vepafestinib (TAS0953/HM06) is an investigational, potent, orally administered, highly selective RET inhibitor, is pharmacologically distinct, exhibits a distinct binding mode to RET, and has shown evidence of enhanced brain penetrability characteristics in preclinical model.
Lead Product(s): Vepafestinib
Therapeutic Area: Oncology Product Name: TAS0953
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Helsinn Advanced Synthesis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
TAS6417 (CLN-081), is designed as a next-generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (NSCLC).
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Cullinan Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Under the agreement, Taiho will acquire Cullinan Oncology’s subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan* to CLN-081/TAS6417, EGFR exon20 non-small cell lung cancer (NSCLC) regulatory milestones.
Lead Product(s): CLN-081
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Cullinan Therapeutics
Deal Size: $405.0 million Upfront Cash: $275.0 million
Deal Type: Collaboration May 12, 2022
Details:
The approval is based on results of a Phase III clinical study (CONSOLE6) comparing the efficacy and safety of Arokaris® versus fosaprepitant in patients receiving highly emetogenic chemotherapy in combination with palonosetron and dexamethasone.
Lead Product(s): Fosnetupitant Chloride
Therapeutic Area: Gastroenterology Product Name: Arokaris
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Taiho exercised its option for anti-TIGIT antibodies domvanalimab (development code: AB154) and AB308 from Arcus Biosciences (“Arcus”), in Japan and certain other territories in Asia (excluding China).
Lead Product(s): Domvanalimab,Zimberelimab
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Arcus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2021
Details:
Taiho Pharmaceutical has submitted to the Japanese Ministry of Health, Labour and Welfare a new drug application for an NK1 receptor antagonist antiemetic drug for gastrointestinal symptoms (nausea and vomiting) associated with cancer chemotherapy.
Lead Product(s): Fosnetupitant Chloride
Therapeutic Area: Gastroenterology Product Name: Pro-NETU
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
